HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

siRNA silencing of PD-L1 and PD-L2 on dendritic cells augments expansion and function of minor histocompatibility antigen-specific CD8+ T cells.

Abstract
Tumor relapse after human leukocyte antigen-matched allogeneic stem cell transplantation (SCT) remains a serious problem, despite the long-term presence of minor histocompatibility antigen (MiHA)-specific memory T cells. Dendritic cell (DC)-based vaccination boosting MiHA-specific T-cell immunity is an appealing strategy to prevent or counteract tumor recurrence, but improvement is necessary to increase the clinical benefit. Here, we investigated whether knockdown of programmed death ligand 1 (PD-L1) and PD-L2 on monocyte-derived DCs results in improved T-cell activation. Electroporation of single siRNA sequences into immature DCs resulted in efficient, specific, and long-lasting knockdown of PD-L1 and PD-L2 expression. PD-L knockdown DCs strongly augmented interferon-γ and interleukin-2 production by stimulated T cells in an allogeneic mixed lymphocyte reaction, whereas no effect was observed on T-cell proliferation. Moreover, we demonstrated that PD-L gene silencing, especially combined PD-L1 and PD-L2 knockdown, resulted in improved proliferation and cytokine production of keyhole limpet hemocyanin-specific CD4(+) T cells. Most importantly, PD-L knockdown DCs showed superior potential to expand MiHA-specific CD8(+) effector and memory T cells from leukemia patients early after donor lymphocyte infusion and later during relapse. These data demonstrate that PD-L siRNA electroporated DCs are highly effective in enhancing T-cell proliferation and cytokine production, and are therefore attractive cells for improving the efficacy of DC vaccines in cancer patients.
AuthorsWillemijn Hobo, Frans Maas, Niken Adisty, Theo de Witte, Nicolaas Schaap, Robbert van der Voort, Harry Dolstra
JournalBlood (Blood) Vol. 116 Issue 22 Pg. 4501-11 (Nov 25 2010) ISSN: 1528-0020 [Electronic] United States
PMID20682852 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Antigens, CD
  • B7-H1 Antigen
  • CD274 protein, human
  • Cytokines
  • Intercellular Signaling Peptides and Proteins
  • Minor Histocompatibility Antigens
  • PDCD1LG2 protein, human
  • Programmed Cell Death 1 Ligand 2 Protein
Topics
  • Antigens, CD (genetics, immunology)
  • B7-H1 Antigen
  • CD8-Positive T-Lymphocytes (cytology, immunology)
  • Cell Proliferation
  • Cells, Cultured
  • Cytokines (immunology)
  • Dendritic Cells (immunology, metabolism)
  • Gene Silencing
  • Humans
  • Intercellular Signaling Peptides and Proteins (genetics, immunology)
  • Minor Histocompatibility Antigens (immunology)
  • Programmed Cell Death 1 Ligand 2 Protein

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: